Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States

BACKGROUND: Standard first-line treatments for advanced soft tissue sarcoma (STS) have changed little for 40 years, and outcomes have been poor. Recently, the United States (US) Food and Drug Administration conditionally approved olaratumab in combination with doxorubicin (Olara + Dox) based on a ra...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Sarcoma
Hoofdauteurs: Zuluaga-Sanchez, Santiago, Hess, Lisa M., Wolowacz, Sorrel E., D'yachkova, Yulia, Hawe, Emma, Vickers, Adrian D., Kaye, James A., Bertwistle, David
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Hindawi 2018
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5892240/
https://ncbi.nlm.nih.gov/pubmed/29785170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/6703963
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items